UAE Plants

JVII - Biotech EPO Plant

JVII - Biotech EPO Plant

Annual capacities: 200 grams of erythropoietin, equivalent 10 million vials

Julphar has launched one of the most advanced biopharmaceutical facilities in the region and has joined the elite group of international players possessing biotechnology product manufacturing capabilities. The Biotech EPO plant has the capacity to meet the demand of erythropoietin production under cGMP for the entire Middle East region and other Julphar markets. The biopharmaceutical manufacturing facility is dedicated for erythropoietin (rHu-EPO) by recombinant Chinese Hamster Ovary (CHO) cell culture technology.